When you talk to leaders who make it to GM, franchise head, or the C‑suite in pharma and biotech, a different pattern shows up: sideways moves into new functions, therapeutic areas, or business models that didn’t look like promotions at the time, but turned out to be pivotal.

Most platform biotechs don’t fail on science—they fail because investors don’t believe the team can turn that science into a real, defensible engine. This post breaks down what VCs are actually trying to de‑risk in a platform biotech, how your first five hires map to those concerns, and the concrete artifacts (org map, hiring plan, scorecards, RA/QA and BD thinking) you can bring to a pitch to show you’re building a fundable team, not just a cool idea.

Ask any Specialty Pharma leader what they want in their next executive hire and you’ll hear familiar themes: “fresh thinking,” “diverse perspectives,” “ability to challenge the status quo.” Then the search progresses, and a strong candidate gets rejected with a vague line: “They’re great, but I’m not sure they’re a culture fit.” In many organizations, that is where diverse, high‑potential leaders—especially those who don’t look, talk, or network like the current C‑suite—qui

A Practical lens for Board Members - Will this PI Founder still be CEO by Series B? Most European life sciences funds back companies where the founding CEO is a first‑time scientific leader: a PI out of a top lab, an ex‑pharma director, sometimes a computational founder with limited management experience. Very few investment memos say, “And we expect to replace them before Series B.” Yet that’s exactly what happens in a lot of cases—not always for the wrong reasons, but often